Population health model predicting the long-term impact of sotatercept on morbidity and mortality in patients with Pulmonary Arterial Hypertension (PAH)

被引：0

作者：

Mclaughlin, Vallerie ^{[1
]}

Alsumali, Adnan ^{[2
]}

Klok, Rogier ^{[2
]}

Liu, Rongzhe ^{[3
]}

Martinez, Eliana ^{[2
]}

Chevure, Jestinah ^{[2
]}

Pena, Janethe De Oliveira ^{[2
]}

Lautsch, Dominik ^{[2
]}

Hoeper, Marius ^{[4
,5
]}

机构：

[1] Univ Michigan Hlth Syst, Dept Internal Med, Div Cardiovasc Med, Ann Arbor, MI USA

[2] Merck & Co Inc, Rahway, NJ 07065 USA

[3] OPEN Hlth, Bethesda, MD USA

[4] Hannover Med Sch, Dept Resp Dis, Hannover, Germany

[5] Hannover Med Sch, German Ctr Lung Res DZL, Hannover, Germany

来源：

EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷

关键词：

D O I：

10.1183/13993003.congress-2023.OA740

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：3

共 50 条

[31] Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Sitbon, Olivier
Channick, Richard
Chin, Kelly
Frey, Aline
Galie, Nazzareno
Ghofrani, Hossein-Ardeschir
Hoeper, Marius M.
Lang, Irene
Le Brun, Franck-Olivier
McLaughlin, Vallerie
Preiss, Ralph
Rubin, Lewis J.
Simonneau, Gerald
Tapson, Victor
Gaine, Sean
EUROPEAN RESPIRATORY JOURNAL, 2015, 46
[32] Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)
Preston, Ioana R.
Roberts, Kari E.
Miller, Dave P.
Sen, Ginny P.
Selej, Mona
Benton, Wade W.
Hill, Nicholas S.
Farber, Harrison W.
CIRCULATION, 2015, 132 (25) : 2403 - 2411
[33] EFFICACY AND SAFETY OF LONG-TERM PAH-SPECIFIC MONO-THERAPY WITH BOSENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Paramonov, V.
Martynyuk, T.
Chazova, I. E.
JOURNAL OF HYPERTENSION, 2015, 33 : E195 - E195
[34] Long-term treatment with sitaxsentan in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD)
Girgis, RE
Frost, A
Hill, N
Langleban, D
McLaughlin, V
Oudiz, L
Coyne, T
CHEST, 2005, 128 (04) : 218S - 218S
[35] Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): Results from a long-term randomised controlled trial
Jansa, Pavel
Channick, Richard
Delcroix, Marion
Galie, Nazzareno
Ghofrani, Hossein-Ardeschir
Hunche, Elke
Mehta, Sanjay
Mittelholzer, Camilla
Pulido, Tomas
Sastry, B. K. S.
Sitbon, Olivier
Souza, Rogerio
Torbicki, Adam
Simonneau, Gerald
Rubin, Lewis
EUROPEAN RESPIRATORY JOURNAL, 2013, 42
[36] Reponse to Inhaled Nitric Oxide (iNO) Does Not Predict Long Term Mortality in Pulmonary Arterial Hypertension (PAH)
Rubenfire, M.
Krishnan, S.
Montgomery, D.
McLaughlin, V.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
[37] Long-Term Hepatic Safety of Ambrisentan in Patients With Pulmonary Arterial Hypertension
Ben-Yehuda, Ori
Pizzuti, David
Brown, Andrea
Littman, Marcus
Gillies, Hunter
Henig, Noreen
Peschel, Tobias
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (01) : 80 - U105
[38] Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients
Tahara, Nobuhiro
Dobashi, Hiroaki
Fukuda, Keiichi
Funauchi, Masanori
Hatano, Masaru
Ikeda, Satoshi
Joho, Shuji
Kihara, Yasuki
Kondo, Takahisa
Matsushita, Masakazu
Minamino, Tohru
Nakanishi, Norifumi
Okano, Yoshiaki
Ozaki, Yukio
Saji, Tsutomu
Sakai, Satoshi
Tanabe, Nobuhiro
Watanabe, Hiroshi
Yamada, Hidehiro
Yoshioka, Koichiro
Hatta, Motonori
Sasayama, Shigetake
CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (06) : 921 - 928
[39] Long-term survival of systemic sclerosis with pulmonary arterial hypertension patients
Sirijanchune, Piyaporn
Lhakum, Panomkorn
RESPIROLOGY, 2023, 28 : 26 - 27
[40] Long-term effects with ambrisentan monotherapy in patients with pulmonary arterial hypertension
文莉
ChinaMedicalAbstracts(InternalMedicine), 2014, 31 (03) : 160 - 161

← 1 2 3 4 5 →